No difference between micro-and macroprolactinomas in the prolactin responsiveness to metoclopramide and dopamine administration

References

• Scrri O., Kuchel O., Buu N. T., Somma M. Differential effect of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab. 1983; 56: 255–9
   Google Scholar
• Spada A., Nicosia S., Cortellazzi L., Pezzo G., Bassetti M., Sartorio A., Giannattasio G. In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. J. Gin. Endocrinol. Metab. 1983; 56: 1–10
   PubMedGoogle Scholar
• Maraschini C., Moro M., Masala A., Toja P., Alagna S., Brunani A., Rovasio P. P., Ginanni A., Lancranjan I., Cavagnini F. Chronic treatment with Parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol. (Copenh.) 1991; 125: 494–501
   Google Scholar
• Koike K., Miyake A., Aono T., Sakumoto T., Ohmichi M., Yamaguchi M., Tanizawa O. Effect of prolactin on the secretion of hypothalamic GnRH and pituitary gonadotropins. Harm. Res. 1991; 35(Suppl. 1)5–12
   PubMedGoogle Scholar
• Rodriguez-Arnao M. D., Peters J. R., Foord S. M., Dieguez C I, Edwards C., Gomez-Pan A., Hall R., Newcombe R. G., Scanlon M. F. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyper-prolactinemia: evidence against a hypothalamic dopaminergic defect. J. Clin. Endocrinol. Metab. 1983; 57: 975–80
   PubMed Web of Science ®Google Scholar
• Ghigo E., Goffi S., Molmatti G. M., Camanni F., Massara F. Prolactin and TSH responses to both domperidone and TRH in normal and hypcrprolactinemic women after dopamine synthesis blockade. Clin. Endocrinol. 1985; 23: 155–60
   Google Scholar
• Kovacs K., Use G., Ryan M. Pituitary prolactin cell hyperplasia. Horm. Res. 1980; 12: 87–95
   Google Scholar
• Sarkar 1. K., Gottschall P. E., Meites J. Decline of tuberoinfundibular dopaminergic function resulting from chronic hyperprolac-tincmin m rats. Endocrinology 1984; 115: 1269–74
   Google Scholar
• Paradisi R., Grossi G., Pintore A., Venturoli S., Porcu E., Capelh M., Flamigni C. Evidence for a pathological reduction in brain dopamine metabolism in idiopathic hyper-prolactinemia. Acta Endocrinol. (Copenh.) 1991; 125: 246–52
   Google Scholar
• Nicoletti I., Filippom P., Fedeh L., Ambrosi F., Giammartino C., Spmozzi F., Santeusanio F. Catecholamines and pituitary function. IV. Effects of low-dose dopamine infusion and long-term bromocriptine treatment on the abnormal thyrotroph (TSH) dynamics in patients with pathological hyperprolactinemia. Acta Endocrinol. (Co-path.). 1986; 111: 154–61
   Google Scholar
• Simpkins J. W., Gabriel S. M. Chronic hvperprolactinemia causes progressive changes in hypothalamic dopaminergic and noradrenergic neurons. Brain Res. 1984; 309: 277–82
   Google Scholar
• Bansal S., Lee L. A., Woolf P. D. Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients. Am. J. Med. 1981; 71: 961–6
   PubMedGoogle Scholar
• Lalio D., Malarkey W. B. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas. Am. J. Obstet. Gynecol. 1985; 151: 651–5
   Google Scholar
• Ho K. Y., Smythe G. A., Duncan M., Lazarus L. Dopamine infusion studies in patients with pathological hyperprolactinemia: evidence of normal prolactin suppressibility but abnormal dopamine metabolism. J. Clin. Endocrinol. Metal. 1984; 58: 128–33
   Google Scholar
• Connell J. M. C., Padfield P. L., Bunting E. A., Ball S. G., lnglis G. C., Beastall G. H., Teasdale G. M., Davies D. L. Inhibition of prolactin secretion by low-dose dopamine infusion in patients with hyperprolactinemia. Clin. Endocrinol. 1983; 18: 527–32
   PubMedGoogle Scholar
• Ho K. Y., Smythe G. A., Lazarus L. Normal lactotroph sensitivity to graded low-dose dopamine infusion in pathological hyperprolactinemia. Nenroendocrinology 1986; 43: 175–81
   Google Scholar
• Bethea C. L., Ramsdell J. S., Jaffe R. B., Wilson C. B., Werner R. I. Characterization of the dopaminergic regulation of human prolac-tin-secreting cells cultured on extracellular matrix. J. Clin. Endocrinol. Metab. 1982; 54: 893–902
   Google Scholar
• Camanni F., Genazzani A. R., Massara F., La Rosa R., Cocchi D., Miiller E. E. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Neuroendocrinology 1980; 30: 2–6
   Google Scholar
• Nicoletti I., Ambrosi F., Paghacci M. C., Pelicci G., Giammartino G., Maggio D., Fedeli L., Filipponi P. Catecholamines and pituitary function. VI. Effect of different dopamine doses on TRH-induced prolactin release in women with pathological hyperprolactinemia. Horm. Metab. Res. 1987; 19: 125–9
   Google Scholar
• Quigley M. E., Judd S. J., Gilliland G. B., Yen S. S. C. Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. J. Clin. Endocrinol. Metab. 1980; 50: 994–8
   Google Scholar
• Müller E. E., Cavagnini F., Martinez-Campos A., Maraschini C., Giovanmni P., Novelli A., De Leo V. Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders. Acta Endocrinol. (Copenh.) 1984; 107: 155–63
   Google Scholar
• Del Pozo E., Varga L., Wyss H., Tolis G., Friesen H., Wenner R., Vetter L., Uettwiler A. Clinical and hormonal response to bro-mocriptin (CB-154) in the galactorrhea syndrome. J. Clin. Endocrinol Metab. 1974; 39: 18–26
   PubMed Web of Science ®Google Scholar
• Malarkey W. Nonpuerperal lactation and normal prolactin regulation. J. Clin. Etidocritioi. Metab. 1975; 40: 198–204
   Google Scholar
• Healy D. L., Pepperell R. J., Stockdale J., Bremncr W. J., Burger H. G. Pituitary autonomy in hyperprolactinemic secondary amenorrhea: results of hypothalamic-pituitary testing. J. Clin. Endocrinol. Metab. 1 977; 44: 809–19
   Google Scholar
• Nyboe Andersen A., Hagen C., Boesgaard S., Eldrup E., Djursing H. Possible thyrotrophs insensitivity to dopamine in hyperprolac-tinemic amenorrhoeic patients. Horm. Metab. Res. 1989; 21: 328–30
   Google Scholar
• Ferrari C., Rampini P., Benco R., Caldara R., Scarduelli C., Crosignani P. G. Functional characterization of hypothalamic hyper-prolactinemia. J. Clin. Endocrinol. Metab. 1982; 55: 897–901
   Google Scholar
• Erroi A., Bassetti M., Spada A., Giannattasio G. Microvasculature of human micro-and macroprolactinomas. A morphological study. Neuroendocrinology 1986; 43: 159–65
   Google Scholar
• Schechter J., Goldsmith P., Wilson C., Weiner R. Morphological evidence for the presence of arteries in human prolactinomas. J. Clin. Endocrinol. Metab. 1988; 67: 713–19
   Google Scholar
• Gorczyca W., Hardy J. Microadenomas of the human pituitary and their vascularization. Neurosurgery 1988; 22: 1–6
   PubMedGoogle Scholar
• Reichlin S., Molitch M. Neuroendocrine aspects of pituitary adenoma. Pituitary hyperfunction, F. Camanni, E. E. Muller. Raven Press, New York 1984; 47–52
   Google Scholar